在小细胞肺癌中，对手术切除标本、配对组织微阵列和淋巴结转移中ASCL1、NEUROD1和POU2F3表达的比较。
Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma.
发表日期：2023 Jan 30
作者：
Takafumi Handa, Takuo Hayashi, Ayako Ura, Isamu Watanabe, Kazuya Takamochi, Hiroko Onagi, Monami Kishi, Naohisa Matsumoto, Ken Tajima, Satsuki Kishikawa, Tsuyoshi Saito, Kazuhisa Takahashi, Kenji Suzuki, Takashi Yao
来源：
HISTOPATHOLOGY
摘要：
小细胞肺癌的亚型是由ASCL1、NEUROD1和POU2F3标记物的表达定义的。我们的研究旨在探索ASCL1、NEUROD1和POU2F3的肿瘤内异质性在外科样本及其匹配组织微阵列（TMA）和淋巴结（LN）转移部位中对这些标记物表达的差异所起的作用。 方法和结果：该队列包括77例SCLC患者。 对原发肿瘤、配对TMA和转移LN部位的整个切片进行了免疫组化检查。 H分数大于50的样本被视为阳性。 根据ASCL1、NEUROD1和POU2F3染色模式，我们将肿瘤分为以下几类：ASCL1优势（SCLC-A），NEUROD1优势（SCLC-N），ASCL1 / NEUROD1双阴性并具有POU2F3表达（SCLC-P），以及对所有三种标记物都为阴性（SCLC-I）。 在整个切片中，确定了40个SCLC-A（52%），20个SCLC-N（26%），15个SCLC-P（20%）和两个SCLC-I（3%）肿瘤。 TMA或LN转移部位与相应的手术标本比较显示，在TMA（所有P <0.0001）或LN转移部位（ASCL1，P =0.0047；NEUROD1，P =0.0069；POU2F3，P <0.0001）中的ASCL1、NEUROD1和POU2F3的阳性与相应的手术标本显著相关。 结论：这些标记物在TMA和LN转移部位中的阳性与相应的手术标本显著相关，表明活检样本可用于鉴定患者的小细胞肺癌分子亚型。© 2023 John Wiley＆Sons Ltd。
Subtypes of small cell lung carcinoma (SCLC) are defined by the expression of ASCL1, NEUROD1, and POU2F3 markers. The aim of our study was to explore the extent to which the intratumoral heterogeneity of ASCL1, NEUROD1, and POU2F3 may lead to discrepancies in expression of these markers in surgical samples and their matched tissue microarray (TMA) and lymph node (LN) metastatic sites. METHODS AND RESULTS: The cohort included 77 patients with SCLC. Immunohistochemical examinations were performed on whole slides of the primary tumour, paired TMAs, and metastatic LN sites. Samples with H-scores >50 were considered positive. Based on the ASCL1, NEUROD1, and POU2F3 staining pattern, we grouped the tumours as follows: ASCL1-dominant (SCLC-A), NEUROD1-dominant (SCLC-N), ASCL1/NEUROD1 double-negative with POU2F3 expression (SCLC-P), and negative for all three markers (SCLC-I). In whole slides, 40 SCLC-A (52%), 20 SCLC-N (26%), 15 SCLC-P (20%), and two SCLC-I (3%) tumours were identified. Comparisons of TMAs or LN metastatic sites and corresponding surgical specimens showed that positivity for ASCL1, NEUROD1, and POU2F3 in TMAs (all P < 0.0001) or LN metastatic sites (ASCL1, P = 0.0047; NEUROD1, P = 0.0069; POU2F3, P < 0.0001) correlated significantly with that of corresponding surgical specimens. CONCLUSION: The positivity for these markers in TMAs and LN metastatic sites was significantly correlated with that of corresponding surgical specimens, indicating that biopsy specimens could be used to identify molecular subtypes of SCLC in patients.© 2023 John Wiley & Sons Ltd.